Gut dysbiosis can result in several diseases, including infections (Clostridium difficile infection and infectious gastroenteritis), autoimmune diseases (inflammatory bowel disease, diabetes, and allergic disorders), behavioral disorders and other conditions like metabolic syndrome and functional gastrointestinal disorders. Amongst various therapies targeting gut microbiome, fecal microbiota transplantation (FMT) is becoming a focus in the public media and peer reviewed literature. We have been using FMT for induction of remission in patients with moderate to severe active ulcerative colitis (UC) and also for subsequent maintenance of remission. Four cases reported incidental benefits while being treated with FMT for UC. These included weight loss (n=1), improvement in hair loss (n=1), amelioration of axial arthritis (n=1) and improvement in allergic rhinitis (n=1), thereby suggesting potential clinical applications of FMT in treating extraintestinal diseases associated with gut dysbiosis.
Citations
Citations to this article as recorded by
Fecal microbiota transplantation in allergic diseases Ece Tüsüz Önata, Öner Özdemir World Journal of Methodology.2025;[Epub] CrossRef
16S rRNA sequencing-based evaluation of the protective effects of key gut microbiota on inhaled allergen-induced allergic rhinitis Yi Tang, Yongchuan She, Danping Chen, Yibo Zhou, Dan Xie, Zhai Liu Frontiers in Microbiology.2025;[Epub] CrossRef
α‐Lipoic acid alleviates dextran sulfate sodium salt‐induced ulcerative colitis via modulating the Keap1–Nrf2 signaling pathway and inhibiting ferroptosis Peng Jiang, Zongzhen Zhai, Linxian Zhao, Kai Zhang, Liwei Duan Journal of the Science of Food and Agriculture.2024; 104(3): 1679. CrossRef
Effects of dietary imbalances of micro- and macronutrients on the ocular microbiome and its implications in dry eye disease Madeline Pilkington, Declan Lloyd, Brad Guo, Stephanie L. Watson, Kenneth Gek-Jin Ooi Exploration of Medicine.2024; : 127. CrossRef
Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi Intestinal Research.2023; 21(1): 148. CrossRef
Case report: Fecal microbiota transplantation in refractory ankylosing spondylitis Lei Wang, Zhimin Wei, Fei Pan, Chuan Song, Lihua Peng, Yunsheng Yang, Feng Huang Frontiers in Immunology.2023;[Epub] CrossRef
Gut-spine axis: a possible correlation between gut microbiota and spinal degenerative diseases Tadatsugu Morimoto, Takaomi Kobayashi, Toshihiko Kakiuchi, Motohiro Esaki, Masatsugu Tsukamoto, Tomohito Yoshihara, Hirohito Hirata, Shoji Yabuki, Masaaki Mawatari Frontiers in Microbiology.2023;[Epub] CrossRef
Gut microbiota changes in patients with spondyloarthritis: A systematic review Lei Wang, Yiwen Wang, Pei Zhang, Chuan Song, Fei Pan, Gang Li, Lihua Peng, Yunsheng Yang, Zhimin Wei, Feng Huang Seminars in Arthritis and Rheumatism.2022; 52: 151925. CrossRef
Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases Yun Wang, Sheng Zhang, Thomas J. Borody, Faming Zhang Chinese Medical Journal.2022; 135(16): 1927. CrossRef
Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review Xinpei Gu, Qin Lu, Chengcheng Zhang, Zhewei Tang, Liuxi Chu Seminars in Liver Disease.2021; 41(04): 495. CrossRef
Intestinal microbiota and inflammatory bowel diseases Chang Soo Eun Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef
Background/Aims Exclusive enteral nutrition (EEN) is recommended for induction of remission in pediatric Crohn’s disease (CD). However, it is not currently recommended for inducing remission in adults. This report describes the use of 12-week EEN for induction of remission in anti-tumor necrosis factor (anti-TNF) refractory adult CD.
Methods This is a retrospective analysis of adults with moderate to severe active (Crohn’s Disease Activity Index [CDAI] >220) anti-TNF refractory CD, who received EEN for 12 weeks between April 2018 and March 2019 at Dayanand Medical College and Hospital, Ludhiana, India. Primary outcomes included achievement of clinical remission and fistula healing at 12 weeks. Improvement in inflammatory markers and nutritional status were the secondary end points.
Results Out of 23 patients who received anti-TNF agents, 7 (30.4%) were refractory and were offered EEN as a salvage therapy. Six patients (66.7% females, mean age 25.6±6.5 years) consented. Four patients (66.6%) achieved clinical remission (CDAI <150). Mean CDAI of patients decreased significantly after 12 weeks of EEN (388.8±74.8 vs. 160.0±25.2, P<0.001). Perianal fistulas showed clinical response (drainage decreased by >50%), though none achieved remission. Entero-enteric fistulae showed complete healing. Mean body mass index improved from 15.6±3.1 to 18.9±1.9 kg/m2 at week 12 (P=0.003). Hemoglobin and serum albumin also improved from 8.2±1.1 g/dL and 2.8±0.3 g/dL at baseline to 12.6±0.6 g/dL and 3.6±0.5 g/dL post-EEN respectively (P<0.001 and P=0.006 respectively).
Conclusions EEN appears to be an effective and well tolerated therapy for induction of remission in anti-TNF refractory adult CD. More data from prospective trials with larger number of patients is required.
Citations
Citations to this article as recorded by
Efficacy of exclusive enteral nutrition as a salvage therapy in adults with Crohn’s disease refractory to biologic treatment Yuchan Yang, Feng Zhu, Qiong Wu, Jiansheng Wang, Xueni Qiu, Song Li, Yi Xu, Jianfeng Gong Nutrition.2026; 143: 113007. CrossRef
Adjunct polymeric exclusive enteral nutrition helps achieve biochemical remission in active Crohn’s disease in adults irrespective of disease location and concomitant corticosteroid use Hellen Kuo, Katrina Tognolini, Rumbidzai Mutsekwa, Dheeraj Shukla, Laura Willmann, Hadi Moattar, Alexander Dorrington, Naveed Ishaq, Maneesha Bhullar, John Edwards, Waled Mohsen, Pradeep Kakkadasam Ramaswamy Frontline Gastroenterology.2025; 16(1): 3. CrossRef
Enteral Nutrition in Crohn’s Disease: A Comprehensive Review of Its Role in Induction and Maintenance of Remission and Perioperative Management in Adult Patients André Bargas, Carolina Palmela, Luisa Glória Nutrients.2025; 17(9): 1481. CrossRef
Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD) Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin Česko-slovenská pediatrie.2024; 79(4): 213. CrossRef
Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn’s disease: A cohort study from northern India Arshdeep Singh, Chandan Kakkar, Shreya Garg, Kirti Arora, Vandana Midha, Ramit Mahajan, Satpal Singh Virk, Narender Pal Jain, Dharmatma Singh, Kriti Sood, Ashish Tripathi, Dhruv Gupta, Ishita Gupta Kaushal, Ritu Dhawan Galhotra, Kavita Saggar, Ajit Sood Indian Journal of Gastroenterology.2023; 42(5): 668. CrossRef
Use of oral diet and nutrition support in management of stricturing and fistulizing Crohn's disease Kush Fansiwala, Neha D. Shah, Kelly A. McNulty, Mary R. Kwaan, Berkeley N. Limketkai Nutrition in Clinical Practice.2023; 38(6): 1282. CrossRef
Incidence and Prevalence of Inflammatory Bowel Disease across Asia Jihye Park, Jae Hee Cheon Yonsei Medical Journal.2021; 62(2): 99. CrossRef
Review of exclusive enteral therapy in adult Crohn’s disease Nikola Mitrev, Hin Huang, Barbara Hannah, Viraj Chandana Kariyawasam BMJ Open Gastroenterology.2021; 8(1): e000745. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review Ji Young Chang, Jae Hee Cheon Precision and Future Medicine.2021; 5(4): 151. CrossRef
Enteral nutrition in the biologic era: learn from yesterday, live for today, hope for tomorrow Tadakazu Hisamatsu Intestinal Research.2020; 18(2): 139. CrossRef